Professor David Fairlie

Professiorial Research Fellow - GL

Institute for Molecular Bioscience

Affiliated Professor

School of Chemistry and Molecular Biosciences
Faculty of Science
d.fairlie@imb.uq.edu.au
+61 7 334 62989
+61 7 334 62381

Overview

Professor Fairlie is an NHMRC Senior Principal Research Fellow (2012-2021), one of three Division Heads of the Institute for Molecular Bioscience (since 2009), and an Affiliate Professor of the School of Chemistry and Molecular Biosciences. He was previously an ARC Federation Fellow (2006-2011), an ARC Professorial Fellow (2002-2006), Scientific Director and Chief Scientific Officer of a startup company, completed his postdoctoral studies at Stanford University and University of Toronto, postgraduate studies at Australian National University and University of New South Wales, and undergraduate studies at University of Adelaide.

His research group works across the disciplines of chemistry (synthesis, structure, reaction mechanisms), biochemistry (enzyme inhibitors, protein-protein interactions, GPCRs, transcription factors), immunology (innate immune cells in health and disease, mucosal T cells), and pharmacology (molecular pharmacology and human cell signalling, experimental pharmacology in rodent models of human disease). He has published over 400 scientific journal articles in high impact chemistry journals (e.g. Chem Rev, J Am Chem Soc, Angew Chem Int Edit, Chem Sci, J Med Chem, Org Lett, J Org Chem) and biology journals (e.g. Nature, Science, Nature Immunology, Immunity, Science Immunology, Nature Communications, J Exp Med, J Clin Invest, Proc Natl Acad Sci, Diabetes, Cancer Res, Br J Pharmacol). He has been a Highly Cited Researcher (Clarivate Analytics), with around 30,000 citations and 70 publications with over 100 citations (Google Scholar), and has collaborated with many of the world’s largest pharmaceutical and biotechnology companies.

Research Interests

  • Chemistry and Human Therapeutics
    The Fairlie group works at the interface of chemistry, biology and disease. We study CHEMISTRY, BIOCHEMISTRY, PHARMACOLOGY and IMMUNOLOGY to better understand the detailed processes of life, ageing, disease and death. Our chemists use state of the art methods to invent new compounds that regulate enzymes, cellular receptors, RNA or DNA. Our biochemists, pharmacologists and immunologists study enzymes, proteins, cells and rodents to study biological processes and effects of novel compounds in models of human disease. We elucidate mechanisms of chemical reactions, biological processes, disease development and drug action. We aim to develop new treatments for human inflammatory diseases, cancers, metabolic diseases (type 2 diabetes, obesity, cardiovascular), viral infections and neurodegenerative disorders (e.g. Alzheimer’s disease). We also execute basic research to understand fundamental principles and processes in chemistry (medicinal, organic, biological, computational, bioinorganic), biochemistry (proteins, enzymes), pharmacology (cells, rodents, human tissues) and immunology (neutrophils, macrophages, mast cells, dendritic cells, complement, T cells, rodents).
  • Medicinal and Organic Chemistry
    We develop skills in chemical synthesis, structure elucidation and chemical mechanisms. We design new molecules with the aid of computers, develop new methods to synthesize them, determine their structures, elucidate reaction mechanisms, and use small molecules to probe biological processes and to elucidate structure-activity relationships. We use a wide range of solution and solid phase organic synthesis methodologies to create bioactive molecules (e.g. de novo designed drugs, natural product analogues, and peptidomimetics), reactive intermediates, highly functionalised molecular templates, structural constraints, and artificial receptors. We also synthesize metal complexes as folding templates, as catalysts for organic reactions, and as models of metalloproteins. We are engaged in chemical design and structural analysis using computers, determination of chemical structures by NMR spectroscopy and X-ray crystallography, spectroscopic investigations of chemical and biological reactions, enzyme kinetics, cell biology, and molecular pharmacology in vitro and in vivo.
  • Biochemistry and Protein-Protein Interactions
    One strategic theme is the development of small molecules to mimic or inhibit bioactive protein surfaces recognized by other proteins. Protein-protein interactions drive most biological processes, yet the vast majority of these interactions occur over very short time scales (fractions of seconds). To better understand such fleeting interactions, we have been developing mimics of protein surfaces and working towards studying their longer-lived interactions with protein partners. We have identified conformations of protein surfaces that are common recognition elements for protease enzymes, for classes of G protein-coupled receptors that act as sensors on cell surfaces, or for transcriptional receptors that mediate DNA-protein responses in cells. We have described small molecules that structurally and functionally mimic components of bioactive protein surfaces (beta strands, beta-sheets, beta and gamma turns, alpha helices, helix bundles, multi-loop bundles). There are numerous potential uses for each of these classes of protein surface mimics - with many potential therapeutic applications. Through the ARC Centre of Excellence for Innovations in Peptide and Protein Science, we are studying post-translational modifications of proteins, elucidating structures and activities of naturally occurring peptides, and designing and developing peptidomimetics with interesting chemical or biological properties.
  • Immunology
    We aim to better understand the molecular basis of the immune response and study aspects of innate and adaptive immunity. Our group works with human neutrophils, macrophages, dendritic cells, mast cells, complement and T cells, investigating their recruitment, differentiation, signalling and modulation in immunity, including the effects of novel drug leads on their functions. We are especially interested in complement proteins, GPCRs, T cell receptors, proteases, HDACs, chemokines and cytokines. Our novel compounds are used to validate targets on human cells and human proteins, then investigated in rodent models of human diseases and then towards preclinical and clinical studies, sometimes with pharma/biotech partners. Understanding how new experimental drugs can stimulate/enhance immune responses or suppress proinflammatory mediators can help in the design and development of effective new therapies to combat a diverse range of important human diseases. Through the ARC Centre of Excellence in Advanced Molecular Imaging, we link up with physicists, structural biologists and immunologists in Melbourne and Sydney to study the molecular basis of T cell mediated immunity. Through collaborations with IMB Centre for Inflammation and Disease Research in Brisbane, we study innate immunity.
  • Molecular and Experimental Pharmacology
    Our research on diseases involves basic, strategic and applied research in biochemistry and pharmacology directed at: (1) understanding how the immune system resolves infection (by parasites, viruses, bacteria) and tissue injury; (2) how prolonged inflammatory responses can cause debilitating chronic inflammatory diseases, including onset of cancers, metabolic diseases (obesity, type 2 diabetes, atherosclerosis, cardiovascular diseases), chronic inflammatory pain, and neurodegenerative diseases (e.g. Alzheimer's disease); and (3) how our novel compounds can act on human proteins, human and rodent cells and tissues, and rat or mouse models of human diseases. See links for our publications in all of these disease areas and allied chemical, biochemical and pharmacological research. We conduct molecular pharmacology (studies of novel ligand interactions with cellular receptors, modulation of intracellular signalling pathways using experimental new drugs discovered in our labs, mechanisms of physiological responses and disease induction/progression) and experimental pharmacology (studies of drug-induced effects in rodent models of human diseases, interrogating molecular mechanisms in vivo, examining human tissues from the clinic). Our goal is to discover new drugs, mechanisms of drug action and to understand disease development and how to treat it.

Research Impacts

Our researchers work at interfaces of chemistry and biology to better understand the molecular mechanisms of life, ageing, disease and death.

Our chemists study organic, medicinal and biological chemistry, especially using organic synthesis, computer-aided molecular design, nuclear magnetic resonance spectroscopy to create new chemical structures that interact with or mimic protein surfaces. We discover new chemical structures, reactions and mechanisms; enzyme inhibitors, agonists and antagonists of protein function; and molecules that mimic the structures and functions of bioactive protein surfaces.

Our biologists study mechanisms of protein and cell activation, signalling pathways, biological processes, disease development and drug action. We use novel experimental compounds discovered in our group as molecular tools to interrogate the functions of human proteins and cells, and apply some of them to the treatment of animal models of human diseases.

Our interdisciplinary expertise can be combined across multiple subdisciplines of chemistry and biology to gain insights into biochemical processes, human physiology, disease pathology, and we develop skills in biochemistry, pharmacology, virology, immunology, oncology or neurobiology. We work, in some cases with industry partners, to discover new basic research and apply some of our discoveries to develop experimental treatments for viral or parasitic infections, such as HIV, dengue fever and malaria; inflammatory diseases, such as arthritis, asthma, inflammatory bowel disease and rare immunological disorders; metabolic and cardiovascular disorders linked to obesity and type 2 diabetes; neurodegenerative diseases and cancers.

Qualifications

  • PhD, University of New South Wales
  • BSc(Hons), The University of Adelaide

Publications

  • Tng, Jiahui, Lim, Junxian, Wu, Kai-Chen, Lucke, Andrew J., Xu, Weijun, Reid, Robert C. and Fairlie, David P. (2020). Achiral derivatives of hydroxamate AR-42 potently inhibit class I HDAC enzymes and cancer cell proliferation. Journal of Medicinal Chemistry, 63 (11) acs.jmedchem.0c00230, 5956-5971. doi: 10.1021/acs.jmedchem.0c00230

  • Awad, Wael, Ler, Geraldine J. M., Xu, Weijun, Keller, Andrew N., Mak, Jeffrey Y. W., Lim, Xin Yi, Liu, Ligong, Eckle, Sidonia B. G., Le Nours, Jérôme, McCluskey, James, Corbett, Alexandra J., Fairlie, David P. and Rossjohn, Jamie (2020). The molecular basis underpinning the potency and specificity of MAIT cell antigens. Nature Immunology, 21 (4), 400-411. doi: 10.1038/s41590-020-0616-6

  • Hoang, Huy N., Wu, Chongyang, Hill, Timothy A., Dantas de Araujo, Aline, Bernhardt, Paul V., Liu, Ligong and Fairlie, David P. (2019). A novel long-range n to π* interaction secures the smallest known α-helix in water. Angewandte Chemie International Edition, 58 (52) ange.201911277, 18873-18877. doi: 10.1002/anie.201911277

  • Meade, Richard M., Fairlie, David P. and Mason, Jody M. (2019). Alpha-synuclein structure and Parkinson's disease - Lessons and emerging principles. Molecular Neurodegeneration, 14 (1) 29, 29. doi: 10.1186/s13024-019-0329-1

  • Loh, Zhixuan, Fitzsimmons, Rebecca L., Reid, Robert C., Ramnath, Divya, Clouston, Andrew, Gupta, Praveer K., Irvine, Katharine M., Powell, Elizabeth E., Schroder, Kate, Stow, Jennifer L., Sweet, Matthew J., Fairlie, David P. and Iyer, Abishek (2019). Inhibitors of class I histone deacetylases attenuate thioacetamide-induced liver fibrosis in mice by suppressing hepatic Type 2 inflammation. British Journal of Pharmacology, 176 (19) bph.14768, 3775-3790. doi: 10.1111/bph.14768

  • Hoang, Huy N., Hill, Timothy A., Ruiz-Gómez, Gloria, Diness, Frederik, Mason, Jody M., Wu, Chongyang, Abbenante, Giovanni, Shepherd, Nicholas E. and Fairlie, David P. (2019). Twists or turns: stabilising alpha vs. beta turns in tetrapeptides. Chemical Science, 10 (45), 10595-10600. doi: 10.1039/c9sc04153b

  • Wu, Chongyang, Hoang, Huy N, Liu, Ligong and Fairlie, David P (2018). Glucuronic acid as a helix-inducing linker in short peptides. Chemical Communications, 54 (17), 2162-2165. doi: 10.1039/c7cc09785a

  • Lohman, Rink-Jan, Hamidon, Johan K., Reid, Robert C., Rowley, Jessica A., Yau, Mei-Kwan, Halili, Maria A., Nielsen, Daniel S., Lim, Junxian, Wu, Kai-Chen, Loh, Zhixuan, Do, Anh, Suen, Jacky Y., Iyer, Abishek and Fairlie, David P. (2017). Exploiting a novel conformational switch to control innate immunity mediated by complement protein C3a. Nature Communications, 8 (1) 351, 351. doi: 10.1038/s41467-017-00414-w

  • Mak, Jeffrey Y. W., Xu, Weijun, Reid, Robert C., Corbett, Alexandra J., Meehan, Bronwyn S., Wang, Huimeng, Chen, Zhenjun, Rossjohn, Jamie, McCluskey, James, Liu, Ligong and Fairlie, David P. (2017). Stabilizing short-lived Schiff base derivatives of 5-aminouracils that activate mucosal-associated invariant T cells. Nature Communications, 8 (1) 14599, 14599. doi: 10.1038/ncomms14599

  • Dantas De Araujo, Aline, Lim, Junxian, Good, Andrew C., Skerlj, Renato T. and Fairlie, David P. (2017). Electrophilic helical peptides that bond covalently, irreversibly, and selectively in a protein-protein interaction site. ACS Medicinal Chemistry Letters, 8 (1), 22-26. doi: 10.1021/acsmedchemlett.6b00395

  • Bardou, Oliver, Menou, Awen, Francois, Charlene, Duitman, Jan Willem, von der Thusen, Jan H., Borie, Raphael, Sales, Katiuchia Uzzun, Mutze, Kathrin, Castier, Yves, Sage, Edouard, Liu, Ligong, Bugge, Thomas H., Fairlie, David P., Konigshoff, Melanie, Crestani, Bruno and Borensztain, Keren S. (2015). Membrane-anchored serine protease matriptase is a trigger of pulmonary fibrogenesis. American Journal of Respiratory and Critical Care Medicine, 193 (8), 847-860. doi: 10.1164/rccm.201502-0299OC

  • Nielsen, Daniel S., Hoang, Huy N., Lohman, Rink-Jan, Hill, Timothy A., Lucke, Andrew J., Craik, David J., Edmonds, David J., Griffith, David A., Rotter, Charles J., Ruggeri, Roger B., Price, David A., Liras, Spiros and Fairlie, David P. (2014). Improving on nature: making a cyclic heptapeptide orally bioavailable. Angewandte Chemie - International Edition, 53 (45), 12059-12063. doi: 10.1002/anie.201405364

  • Hill, Timothy A., Shepherd, Nicholas E., Diness, Frederik and Fairlie, David P. (2014). Constraining cyclic peptides to mimic protein structure motifs. Angewandte Chemie (International Edition), 53 (48), 13020-13041. doi: 10.1002/anie.201401058

  • Suen, J. Y., Cotterell, A., Lohman, R. J., Lim, J., Han, A., Yau, M. K., Liu, L., Cooper, M. A., Vesey, D. A. and Fairlie, D. P. (2014). Pathway-selective antagonism of proteinase activated receptor 2. British Journal of Pharmacology, 171 (17), 4112-4124. doi: 10.1111/bph.12757

  • Reid, Robert C., Yau, Mei-Kwan, Singh, Ranee, Lim, Junxian and Fairlie, David P. (2014). Stereoelectronic effects dictate molecular conformation and biological function of heterocyclic amides. Journal of the American Chemical Society, 136 (34), 11914-11917. doi: 10.1021/ja506518t

  • Vadrevu, Saurya Kumari, Chintala, Navin K., Sharma, Sharad K., Sharma, Priya, Cleveland, Clayton, Riediger, Linley, Manne, Sasikanth, Fairlie, David P., Gorczyca, Wojciech, Almanza, Othon, Karbowniczek, Magdalena and Markiewski, Maciej M. (2014). Complement c5a receptor facilitates cancer metastasis by altering t-cell responses in the metastatic niche. Cancer Research, 74 (13), 3454-3465. doi: 10.1158/0008-5472.CAN-14-0157

  • Corbett, Alexandra J., Eckle, Sidonia B. G., Birkinshaw, Richard W., Liu, Ligong, Patel, Onisha, Mahony, Jennifer, Chen, Zhenjun, Reantragoon, Rangsima, Meehan, Bronwyn, Cao, Hanwei, Williamson, Nicholas A., Strugnell, Richard A., Van Sinderen, Douwe, Mak, Jeffrey Y. W., Fairlie, David P., Kjer-Nielsen, Lars, Rossjohn, Jamie and McClusky, James (2014). T-cell activation by transitory neo-antigens derived from distinct microbial pathways. Nature, 509 (7500), 361-365. doi: 10.1038/nature13160

  • Reid, Robert C., Yau, Mei-Kwan, Singh, Ranee, Hamidon, Johan K., Reed, Anthony N., Chu, Peifei, Suen, Jacky Y., Stoermer, Martin J., Blakeney, Jade S., Lim, Junxian, Faber, Jonathan M. and David P. Fairlie, (2013). Downsizing a human inflammatory protein to a small molecule with equal potency and functionality. Nature Communications, 4 (2802) 2802, 1-9. doi: 10.1038/ncomms3802

View all Publications

Grants

View all Grants

Supervision

View all Supervision

Publications

Featured Publications

Book Chapter

  • Mak, Jeffrey Y. W., Xu, Weijun and Fairlie, David P. (2017). Thiazoles in peptides and peptidomimetics. Peptidomimetics I. (pp. 235-266) edited by William D. Lubell. Cham, Switzerland: Springer. doi: 10.1007/7081_2015_176

  • Lohman, Rink-Jan, Harrison, Rosemary S., Ruiz-Gomez, Gloria, Hoang, Huy Ngoc, Shepherd, Nicholas E., Chow, Shiao, Hill, Timothy A., Madala, Praveen K. and Fairlie, David P. (2015). Helix-constrained nociceptin peptides are potent agonists and antagonists of ORL-1 and nociception. Nociceptin opioid. (pp. 1-55) edited by Gerald Litwack. Maryland Heights, MO, United States: Academic Press. doi: 10.1016/bs.vh.2014.10.001

  • Loughlin, Wendy A. and Fairlie, David P. (2011). Recent advances in β-Strand mimetics. Amino acids, peptides and proteins in organic chemistry: protection reactions, medicinal chemistry, combinatorial synthesis. (pp. 129-147) edited by Andrew B. Hughes. Somerset, NJ, United States: Wiley-VCH. doi: 10.1002/9783527631827.ch3

  • Hans, Dhiraj, Young, Paul R. and Fairlie, David P. (2009). Tumor-associated antigenic peptides as vaccine candidates. Tumor-associated antigens. (pp. 303-316) edited by Olivier Gires and Barbara Seliger. Weinheim, Germany: Wiley - VCH Verlag. doi: 10.1002/9783527625970.ch17

  • Reid, Robert, C. and Fairlie, David P. (2008). Parallel synthesis af anticancer, antiinflammatory and antiviral agents derived from L- and D- amino acids. High-throughput lead optimisation in drug discovery. (pp. 177-194) edited by Tushar Kshirsagar. Boca Raton, USA: CRC Press.

  • Harrison, R. S., Sharpe, P. C., Singh, Y. and Fairlie, D. P. (2007). Amyloid peptides and proteins in review. Reviews of physiology, biochemistry and pharmacology. (pp. 1-77) edited by S. G. Amara, B. Bamberg, T. Fleischmann, S. C. Gudermann, S. C. Hebert, R. Jahn, W. J. Lederer, R. Lill, A. Miyajima, S. Offermanns and R. Zechner. Berlin, Germany: Springer. doi: 10.1007/112_2007_0701

  • Taylor, S. M. and Fairlie, D. (2005). Discovery of Potent Cyclic Antagonists of Human C5a Receptors. Structural Biology of the Complement System. (pp. 341-362) edited by I. Morikis and J Lambris. New York: CRC Press, Taylor and Francis.

  • Kelso, M. J. and Fairlie, D. (2003). Current approaches to peptidomimetics. Molecular Pathomechanisms and New Trends in Drug Research. (pp. 579-598) edited by I. Toth and G. Keri. London and New York: Taylor and Francis.

  • Fairlie, D. P. and Reid, R. C. (1997). Mimicking extended conformations of protease substrates: Designing cyclic peptidomimetics to inhibit HIV-1 protease. Advances in amino acid mimetics and peptidomimetics. (pp. 77-107) London: JAI Press Inc.

Journal Article

Conference Publication

  • Fairlie, David, Reid, Robert, Rowley, Jessica, Wu, Kai-Chen, Yau, Mei-Kwan, Lim, Junxian and Iyer, Abishek (2019). Heterocycles for switching GPCR ligand conformation and activity. National Meeting of the American-Chemical-Society (ACS), Orlando Fl, 31 March-4 April 2019. Washington, DC USA: American Chemical Society.

  • Wang, H., Kjer-Nielsen, L., Shi, M., Souza, D. C., Pediongco, T., Cao, H., Kostenko, L., Lim, X., Eckle, S., Meeha, B., Wang, B., Zhu, T., Mak, J., Fairlie, D., Teng, M., Rossjohn, J., Yu, D., Groth, B., McCluskey, J., Strugnell, R., Corbett, A. and Chen, Z. (2019). IL-23 co-stimulation drives antigen-specific MAIT cell activation and enables vaccination against bacterial infection. 17th International Congress of Immunology (IUIS), Beijing, China, 19-23 October, 2019. Weinheim, Germany: WILEY. doi: 10.1002/eji.201970400

  • Han, Y., Ma, F., Ozols, E., Chew, P., Vesey, D., Gobe, G., Morais, C., Lohman, R., Suen, J., Fairlie, D. and Nikolic-Paterson, D. (2018). PAR-2 does not contribute to tubular damage or renal fibrosis in the obstructed kidney. 54th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology (ANZSN), Sydney, Australia, 8–12 September 2018. Richmond, VIC, Australia: Wiley-Blackwell. doi: 10.1111/nep.13441

  • Ramnath, D., Irvine, K., Lukowski, S., Horsfall, L., Loh, K., Clouston, A., Patel, P., Iyer, A., Lampe, G., Stow, J., Schroder, K., Fairlie, D., Powell, J., Powell, E. and Sweet, M. (2018). RNA-sequencing analysis of biopsies from chronic liver disease patients identifies gene signatures associated with progressive liver disease. International Liver Congress (ILC), Paris, France, 11-15 April, 2018. Amsterdam, Netherlands: Elsevier BV. doi: 10.1016/S0168-8278(18)31040-7

  • Varelias, Antiopi, Bunting, Mark, Ormerod, Kate, Koyama, Motoko, Olver, Stuart, Straube, Jasmin, Kuns, Rachel, Robb, Renee, Henden, Andrea, Cooper, Leanne, Lachner, Nancy, Gartlan, Kate, Lantz, Olivier J., Kjer-Nielsen, Lars, Mak, Jeffrey, Fairlie, David, Clouston, Andrew, McCluskey, James, Rossjohn, Jamie, Lane, Steven, Hugenholtz, Phil and Hill, Geoff (2018). Recipient mucosal-associated invariant T cells control graft-versus-host-disease within the colon. Immunology Meeting, Austin Tx, 4-8 May 2018. Bethesda, MD United States: American Association of Immunologists.

  • Stoermer, Martin J., Wickramasinghe, Wasantha A., Byriel, Karl A., Hockless, David C. R., Skelton, Brian W., Sobolev, Alexandre N., White, Alan H., Mak, Jeffrey Y. W. and Fairlie, David P. (2018). Stereoelectronic effects on dienophile separation influence the Diels–Alder synthesis of molecular clefts. 2018 Royal Society of Chemistry Twitter Conference, London, United Kingdom (held online), 6-7 March 2018. London, United Kingdom: Royal Society of Chemistry.

  • Chua, Ming Jang, Do, Darren, Bachu, Prabhakar, Reid, Robert, Fairlie, David, Skinner-Adams, Tina and Andrews, Kathy (2017). Activity of the histone deacetylase (HDAC) inhibitor AR-42 in a murine malaria model. 66th Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH), Baltimore, MD United States, 5-09 November 2017. Deerfield, IL United States: American Society of Tropical Medicine and Hygiene.

  • Jansen, Diahann, Klinken, Elizabeth, Nel, Hendrik, Law, Soi Cheng, Koppejan, Hester, Hameetman, Marjolijn, Liu, Ligong, Corbett, Alexandra, Eckle, Sidonia, Fairlie, David, Toes, Rene E. M., van Gaalen, Floris, Rossjohn, Jamie, McCluskey, James and Thomas, Ranjeny (2017). Mucosal-associated invariant T cells are an important source of TNF in rheumatoid arthritis. 2017 ACR/ARHP Annual Meeting, San Diego, California, 3-8 November 2017. Hoboken, NJ, United States: John Wiley & Sons.

  • Mak, Jeffrey, Xu, Weijun, Reid, Robert, Corbett, Alexandra, Meehan, Bronwyn, Wang, Huimeng, Chen, Zhenjun, Rossjohn, Jamie, McCluskey, James, Liu, Ligong and Fairlie, David (2017). Vitamin B2 related molecules that activate T cells. 254th National Meeting and Exposition of the American-Chemical-Society (ACS) on Chemistry's Impact on the Global Economy, Washington DC, USA, 20-24 August 2017. Washington DC, USA: American Chemical Society.

  • Das Gupta, K., Shakespear, M., Tunny, K., Hohenhaus, D., Bokil, J. N., Iyer, A., Fairlie, A. D. and Sweet, J. M. (2016). Histone deacetylase 7 (HDAC7) regulates a sub-set of TLR-mediated pro-inflammatory responses in macrophages by both deacetylase-dependent and -independent mechanisms. International Congress of Immunology (ICI), Melbourne, Australia, 21-26 August 2016. Hoboken, NJ, United States: Wiley-Blackwell.

  • Gherardin, N. A., Keller, A. N., Woolley, R. E., Le Nours, J., Ritchie, D. S., Neeson, P. J., Birkinshaw, R. W., Eckle, S. B., Waddington, J. N., Liu, L., Fairlie, D. P., McCluskey, J., Pellicci, D. G., Uldrich, A. P., Rossjohn, J. and Godfrey, D., I (2016). A broad family of MR1-restricted T cells. International Congress of Immunology (ICI), Melbourne Australia, 21-26 August 2016. Germany: Wiley.

  • Keller, A. N., Eckle, S. B. G., Xu, W., Liu, L., Hughes, V. A., Mak, J., Meehan, B., Pediongco, T., Birkinshaw, R. W., Chen, Z., Wang, H., Souza, C., Kostenko, L., Corbett, A. J., Purcell, A. W., Fairlie, D. P., McCluskey, J. and Rossjohn, J. (2016). Common drugs modulate mucosal-associated invariant T cell function. International Congress of Immunology (ICI), Melbourne, VIC, Australia, 21-26 August 2016. Germany: Wiley. doi: 10.1002/eji.201670200

  • Eckle, S. B. G., Keller, A. N., Xu, W., Meehan, B., Pediongco, T., Liu, L., Hughes, V. A., Mak, J. Y. W., Birkinshaw, R. W., Chen, Z., Wang, H., D'Souza, C., Kostenko, L., Corbett, A. J., Purcell, A. W., Fairlie, D. P., Rossjohn, J. and McCluskey, J. (2016). Drugs/drug analogues modulate MAIT cell function in an MR1-dependent manner. International Congress of Immunology (ICI), Melbourne, VIC, Australia, 21-26 August 2016. Weinheim, Germany: Wiley - VCH. doi: 10.1002/eji.201670200

  • McCluskey, J., Corbett, A. J., Eckle, S. B. G., Chen, Z., Wang, H., Sun, S., D'Souza, C., Kostenko, L., Reantragoon, R., Meehan, B., Birkinshaw, R. W., Liu, L., Patel, O., Mahony, J., Cao, H., Jackson, D., Williamson, N. A., Strugnell, R. A., Mak, J. Y. W., Van Sinderen, D., Fairlie, D. P., Kjer-Nielsen, L., Godfrey, D., I and Rossjohn, J. (2016). MAIT cells: Friend or Foe in recognising microbial vitamin metabolites presented by the MHC-I-related molecule MR1. International Congress of Immunology (ICI), Melbourne, Australia, August 21-26, 2016. Weinheim, Germany: Wiley. doi: 10.1002/eji.201670200

  • McWilliam, H., Eckle, S., Theodossis, A., Liu, L., Chen, Z., Fairlie, D., Strugnell, R., Mintern, J., McCluskey, J., Rossjohn, J. and Villadangos, J. (2016). MR1 is an endoplasmic reticulum-resident sensor of vitamin B metabolites. International Congress of Immunology (ICI), Melbourne, Australia, 21-26 August 2016 . Weinheim, Germany: Wiley.

  • Tesch, G., Han, Y., Vesey, D., Gobe, G., Lohman, R., Suen, J., Fairlie, D. and Nikolic-Paterson, D. (2016). Pharmacological Inhibition of Protease-Activated Receptor 2 (Par2) Reduces Crescent Formation in Rat Anti-Gbm Disease. 15th Asian Pacific Congress of Nephrology (APCN) and 52nd ANZSN ASM, Perth, WA, Australia, 17–21 September 2016. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/nep.12887

  • Owens, E., Iyer, A., Morais, C., Lohman, R., Suen, J., Johnson, D., Nikolic-Paterson, D., Gobe, G., Fairlie, D. and Vesey, D. (2016). Protease activated-receptor-2 induced inflammation and fibrosis is mediated in part through activation of transforming growth factor-beta signalling. The 15th Asian Pacific Congress of Nephrology (APCN) and 52nd ANZSN ASM, Perth Western Australia, 17–21 September 2016. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/nep.12887

  • Godfrey, D., Koay, H. -F, Gherardin, N., Enders, A., Loh, L., Chen, Z., Corbett, A., Eckle, S., Meehan, B., d'Udekem, Y., Konstantinov, I, Lappas, M., Liu, L., Goodnow, C., Fairlie, D., Rossjohn, J., Kedzierska, K., Berzins, S., McCluskey, J., Uldrich, A. and Pellicci, D. (2016). Thymic precursors to the mucosal-associated invariant T cell lineage. International Congress of Immunology (ICI), Melbourne Australia, 21-26 August 2016. HOBOKEN: WILEY-BLACKWELL.

  • Kok, Woan Mei, Hill, Timothy A., Lohman, Rink-Jan, Hoang, Huy N., Nielsen, Daniel S., Scully, Conor G., Schroeder, Christina I., Colless, Barbara, Bernhardt, Paul V., Edmonds, David, Griffith, David, Rotter, Charles, Ruggeri, Roger, Price, David, Liras, Spiros, Craik, David and Fairlie, David (2015). Cyclic penta- and hexa leucine peptides without N-methylation are orally absorbed. American Chemical Society Meeting, x, 2015. Washington, DC United States: American Chemical Society.

  • Fairlie, David P. , Yau, Mei-Kwan , Hamidon, Johan K. , Singh, Ranee , Lim, Junxian , Suen, Jacky Y. , Rowley, Jessica A. , Lohman, Rink-Jan , Stoermer, Martin J. , Iyer, Abishek and Reid, Robert C. (2015). Downsizing Proteins Without Losing Potency or Function. American Peptide Symposium 2015, Orlando , Florida, United States, 20-25 June 2015. American Peptide Society. doi: 10.17952/24APS.2015.016

  • Hung Nguyen, Heinrichs, Jessica Lauren, Fu, Jianing, Wu, Yongxia, Bastian, David, Schutt, Steven, Daenthanasanmak, Anusara, Dany, Mohammmed, Liu, Chen, Fairlie, David, Tomlinson, Stephen and Yu, Xue-Zhong (2015). Targeting Host Complement C3a/C5a Receptors to Control of Acute Graft-Versus-Host Disease in Mice. 57th Annual Meeting of the American-Society-of-Hematology, Orlando, FL, United States, 5-8 December 2015. Washington, DC, United States: American Society of Hematology.

  • Sakala, Isaac G., Kjer-Nielsen, Lars, Eickhoff, Christopher S., Wang, Xiaoli, Liu, Ligong, Fairlie, David P., Rossjohn, Jamie, McCluskey, James, Hoft, Daniel F. and Hansen, Ted H. (2015). Tetramer identification of functional mouse mucosal associated invariant T (MAIT) cells. 8th International Workshop on Antigen Processing and Presentation, Philadelphia Pa, Jun 10-13, 2014. Oxford United Kingdom: Pergamon Press.

  • Walden, Patricia M., Halili, Maria A., Archbold, Julia K., Lindahl, Fredrik, Fairlie, David P., Inaba, Kenji and Martin, Jennifer L. (2014). Characterization of the alpha-proteobacteria Wolbachia pipientis protein disulphide machinery reveals a regulatory mechanism absent in gamma-proteobacteria. 28th Annual Symposium of the Protein-Society, San Diego, California, 27-30 July 2014. Hoboken, NJ, United States : Wiley-Blackwell.

  • Chow, Shiao Yun, Stoermer, Martin J., Chappell, Keith J., Young, Paul R. and Fairlie, David P. (2013). Novel inhibitors of DENV NS2B/NS3pro protease. 246th National Meeting of the American-Chemical-Society (ACS), Indianapolis in, Sep 08-12, 2013. WASHINGTON: AMER CHEMICAL SOC.

  • Sakala, Isaac, Yankelevich, Wei-Jen, Kjer-Nielsen, Lars, Fairlie, David, Rossjohn, Jamie, McCluskey, James, Hoft, Daniel and Hansen, Ted (2013). How MAIT cells control the growth of intracellular mycobacteria. 100th Annual Meeting of the American Association of Immunologists, Honolulu Hi United States, May 03-07, 2013. Bethesda, MD United States: American Association of Immunologists.

  • Cantley, M., Fairlie, D., Bartold, M., Marino, V, Gupta, P. and Haynes, D. (2013). Targeting Histone Deacetylase 1 (Hdac 1) to Suppress Both Inflammation and Bone Loss in Arthritis. 54th Annual Scientific Meeting of the Australian Rheumatology Association in conjunction with the Rheumatology Health Professionals Association, Perth, WA Australia, 18 -22 May 2013. Richmond, VIC Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/imj.12139

  • Barbero, Sheila, Reid, Robert C., Stoermer, Martin J., Lohman, Rink J. and Fairlie, David P. (2013). Toward more orally bioavailable inhibitors of phospholipase A(2) GIIA (pla2g2a) to treat chronic inflammation. 246th National Meeting of the American-Chemical-Society (ACS), Indianapolis, IN, United States, 8-12 September 2013. Washington, DC, United States: American Chemical Society.

  • Diness, Frederik, Nielsen, Daniel S. and Fairlie, David P. (2012). Concise synthesis of the thiazole-thiazoline fragment of largazole. 243rd National Spring Meeting of the American-Chemical-Society, San Diego Ca, Mar 25-29, 2012. WASHINGTON: AMER CHEMICAL SOC.

  • Diness, Frederik, Begtrup, Mikael Begtrup and Fairlie, David P. (2012). Fluorobenzene derivatives as multifunctional tools. 243rd National Spring Meeting of the American-Chemical-Society, San Diego Ca, Mar 25-29, 2012. WASHINGTON: AMER CHEMICAL SOC.

  • Croker, Daniel E., Halai, Reena, Fairlie, David P. and Cooper, Matthew A. (2012). Ligand-induced dimerisation of the complement C5aR and C5L2 receptors by C5a but not C5a-des Arg. XXIV International Complement Workshop (ICW), Crete, Greece, 10-15 October 2012. Jena, Germany: Urban und Fischer Verlag. doi: 10.1016/j.imbio.2012.08.152

  • Theodossis, Alex, Ruiz-Gomez, Gloria, Gibb, Andrew, Welland, Andrew, Jones, Paul, Fairlie, David and Rossjohn, Jamie (2012). Shedding light on MHC class I antigen loading: A UV-labile peptide ligand approach. 7th International EMBO Workshop on Antigen Presentation and Processing, Amsterdam, Netherlands, 24-27 April 2012. Oxford, United Kingdom: Pergamon. doi: 10.1016/j.molimm.2012.02.094

  • Theodossis, A., Ruiz-Gomez, G., Gibb, A., Welland, A., Jones, P., Fairlie, D. and Rossjohn, J. (2012). Shedding light on MHC class I antigen loading: a UV-labile peptide ligand approach. 32nd European Peptide Symposium "Peptides 2012", Athens, Greece, 02-07 September 2012. West Sussex, United Kingdom: John Wiley and Sons. doi: 10.1002/psc.2447

  • Cantley, M. D., Fairlie, D. P., Bartold, P., Marino, V. and Haynes, D. R. (2011). Inhibiting Histone Deacetylases Expressed in Human Periodontal Tissues Prevents Bone Loss in An Animal Model of Periodontal Disease. IOF Regionals 2nd Asia-Pacific Osteoporosis and Bone Meeting / ANZBMS Annual Scientific Meeting held with the JSBMR, Gold Coast Australia, Sep 04-08, 2011. LONDON: SPRINGER LONDON LTD.

  • Yau, Annika M., Liu, Ligong, Reid, Robert C., Barry, Grant D., Suen, Jacky Y., Lohman, Rink-Jan, Le, Giang T., Cotterell, Adam and Fairlie, David P. (2011). Novel agonists and antagonists for protease activated receptor 2. National Meeting of the American Chemical Society (242nd, ACS, 2011), Denver, CO, U.S.A., 28 August-1 September 2011. WASHINGTON: AMER CHEMICAL SOC.

  • Fairlie, David P., Stoermer, Martin, Lucke, Andrew, Lohman, Rink-Jan, Liu, Ligong and Ruiz-Gomez, Gloria (2011). Towards orally bioavailable peptides and peptidomimetics. 241st National Meeting and Exposition of the American-Chemical-Society (ACS), Anaheim, CA, United States, 27-31 March 2011. Washington, DC, United States: American Chemical Society.

  • Holt, J. R., Monk, P. N., Fairlie, D. P. and Madala, P. Kumar (2010). Modelling of the C5a receptor by iterative mutation. 23rd International National Complement Workshop, New York Ny, Aug 01-05, 2010. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. doi: 10.1016/j.molimm.2010.05.061

  • Vesey David A., Suen, Jacky Yung, Johnson, David W. and Fairlie, David (2010). A Novel Protease-Activated Receptor-2 Antagonist Targeting Inflammation and Proliferation in Human Renal Tubular Epithelial Cells. Kidney Week, American society of Nephrology, Denver Colorado USA, November 16 - 21. Journal of the American Society of Nephrology:

  • Chappell, K. J., Fairlie, D. P., Gan, C. H., Gupta, P. K., Hu, S., Jensen, C. M., Liebscher, S., Martin, J. L., Robin, G., Stoermer M. J., Xu, W. and Young, P. R. (2010). Potent inhibitors of West Nile Virus NS2B/NS3 protease. 6th General Meeting of the International Proteolysis Society, Gold Coast, QLD, Australia, 26-30 October 2009. Berlin, Germany: Walter De Gruyter.

  • Vesey, D., Rajandram, R., Blakeney, J., Suen, J., Johnson, D., Fairlie, D. and Gobe, G. (2010). Protease-activated receptor-2 and renal carcinogenesis. 46th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, Perth Convention and Exhibition Centre, Perth, Western Australia, 12-15 September 2010. Richmond, Vic., Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/j.1440-1797.2010.01377_1.x

  • Liebscher, Susan, Chappell, K. J., Stoermer, Martin J., Watterson, Daniel, Webb, Richard I., Khromykh, Alexander A., Fairlie, David P. and Young, Paul R. (2010). Sneaking up on West Nile Virus NS2B/NS3 protease subcellular activity utilising dye-quenched substrates. PlusStrand 2010: The Ninth International Symposium on Positive-Strand RNA Viruses, Atlanta, GA, U.S.A., 17-21 May 2010.

  • Cantley, M. D., Fairlie, D. P., Bartold, M. P., Rainsford, K. D. and Haynes, D. R. (2009). Inhibition of both class I and class II histone deacetylases is required to effectively inhibit osteoclast bone resorption in vivo and in vitro. 2nd Joint Meeting of the International-Bone-and-Mineral-Society/Australian-New-Zealand-Bone-and-Mineral-Society, Sydney Australia, Mar 21-25, 2009. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/j.bone.2009.01.292

  • Liebscher, S., Chappell, K.J., Stoermer, M.J., Fairlie, D.P. and Young, P.R (2009). Antiviral activity in cell culture of potent inhibitors targeting the West Nile Virus NS2B/NS3 protease. 6th General Meeting of the International Proteolysis Society, Gold Coast , QLD, Australia, 26-30 October, 2009.

  • Fairlie, David P., Madala, Praveen K., Stoermer, Martin J., Suen, Jacky, Barry, Grant and Lohman, Rink-Jan (2009). Regulating protein and peptide activated GPCRs. 229th National Meeting of the American Chemical Society, San Diego, California, 13-17 March 2005. Washington DC, United States: American Chemical Society.

  • Madala, P. K., Stoermer, M., Tyndall, J. D. A., Monk, P. N., Higginbottom, A. and Fairlie, D. P. (2008). COMP 264-Unraveling the mechanism of antagonism for human C5a receptor: Comparison of three structurally different antagonists. 236th National Meeting of the American Chemical Society, Philadelphia, USA, 17-21 August, 2008. Washington, D. C., USA: American Chemical Society.

  • Fairlie, DP, Le, GT, Halili, M, Ruiz-Gomez, G and Abbenante, J (2008). MEDI 256-Activation and inhibition of latent serine proteases, complement factors B and C2. 236th National Meeting of the American Chemical Society, Philadelphia PA, 17-21 August 2008. Atlanta, GA, USA: The American Chemical Society.

  • Andrews, Kathy T., Tran, Thanh N., Lucke, Andrew, Kahnberg, Pia, Lee, G. T., Skinner-Adams, Tina, Gardiner, Donald L. and Fairlie, David P. (2007). Plasmodium falciparum histone deacetylases: Enzymes involved in gene regulation as new antimalarial drug targets. 56th Annual Meeting of the American-Society-of-Tropical-Medicine-and-Hygiene, Philadelphia, PA United States, 04-08 November 2007. Deerfield, IL United States: American Society of Tropical Medicine and Hygiene.

  • Fairlie, David, Gubler, Duane J., Holmes, Edward, Halstead, Scott, Hombach, Joachim, Harris, Eva, Hibberd, Martin, Vasudevan, Subhash, Evans, Thomas G., Keller, Thomas, Gu, Feng, Stephenson, John, Canard, Bruno, Malasit, Prida and Zinkernagel, Rolf (2006). Discussion.

  • Young, Paul, Keller, Thomas, Padmanabhan, R. Pad, Fairlie, David, Hibberd, Martin, Rice, Charles, Canard, Bruno, Vasudevan, Subhash, Screaton, Gavin, Harris, Eva, Gu, Feng, Halstead, Scott, Farrar, Jeremy, Holmes, Edward, Malasit, Prida and Evans, Thomas G. (2006). Discussion. Novartis Foundation.

  • Rice, Charles, Heinz, Franz X., Kuhn, Richard, Harris, Eva, Fairlie, David, Young, Paul, Flamand, Marie, Zinkernagel, Rolf, Halstead, Scott, Evans, Thomas G., Jans, David A. and Screaton, Gavin (2006). Discussion.

  • Rice, Charles, Padmanabhan, R. Pad, Canard, Bruno, Vasudevan, Subhash, Satchidanandam, Vijaya, Fairlie, David, Gamarnik, Andrea and Kuhn, Richard (2006). Discussion.

  • Harris, Eva, Screaton, Gavin, Farrar, Jeremy, Hombach, Joachim, Halstead, Scott, Rice, Charles, Holmes, Edward, Satchidanandam, Vijaya, Young, Paul, Zinkernagel, Rolf, Flamand, Marie, Malasit, Prida and Fairlie, David (2006). Discussion. Novartis Foundation.

  • Rice, Charles, Hibberd, Martin, Gu, Feng, Harris, Eva, Jans, David A., Farrar, Jeremy, Vasudevan, Subhash, Evans, Thomas G., Holmes, Edward, Fairlie, David and Keller, Thomas (2006). Discussion. Novartis Foundation.

  • Rice, Charles, Heinz, Franz X., Young, Paul, Kuhn, Richard, Neyts, Johan, Keller, Thomas, Fairlie, David, Guber, Duane J. and Screaton, Gavin (2006). General discussion I.

  • Beyer, Renee L., Hoang, Huy N., Le, Giang T. and Fairlie, David P. (2006). MEDI 180-Effects of cyclization constraints on helix/turn peptide structures. WASHINGTON: AMER CHEMICAL SOC.

  • Beyer, Renee L., Kelso, Michael J., Reid, Robert C., Le, Giang T. and Fairlie, David P. (2006). MEDI 181-Alpha helix induction in HIV REV34-50 by N-terminal nucleators. WASHINGTON: AMER CHEMICAL SOC.

  • Monk, Peter N., Higginbottom, Adrian, Madala, Praveen K., Tyndall, Joel D. A., Stoermer, Martin and Fairlie, David P. (2006). Defining the ligand binding site on the human C5a receptor. 231st National Meeting of the American-Chemical-Society, Atlanta Ga, Mar 26-30, 2006. WASHINGTON: AMER CHEMICAL SOC.

  • Beyer, Renee L., Kelso, Michael J., Reid, Robert C., Le, Giang T. and Fairlie, David P. (2006). Alpha helix induction in HIV REV34-50 by N-terminal nucleators. 232nd ACS National Meeting, San Francisco, CA, U.S.A., 10-14 September, 2006. American Chemical Society. doi: 10.1021/cen-v084n034.p055

  • Monk, Peter N., Higginbottom, Adrian, Madala, Praveen K., Tyndall, Joel D. A., Stoermer, Martin and Fairlie, David P. (2006). Defining the ligand binding site on the human C5a receptor. The 231st ACS National Meeting, Atlanta, GA, U.S.A., 26-30 March 2006. Washington, D.C.: American Chemical Society.

  • Desai, A., Khlentzos, A., Shepherd, N., Hoang, H. N., Letouze, E., Fairlie, D. and Young, P. R. (2006). Developing antiviral targets for RSV via mutational analysis of HRB and HRC domains using a novel fusion assay system. 13th International Conference of Negative Strand Viruses, Salamanca, 17-22 June, 2006.

  • Ng Mah Lee, Mary, Rice, Charles, Fairlie, David, Zinkernagel, Rolf, Young, Paul, Neyts, Johan, Hibberd, Martin, Holmes, Edward, Heinz, Franz X. and Stephenson, John (2006). Final discussion. Novartis Foundation Symposium 277: New treatment strategies for Dengue and other flaviviral diseases, *, 2006. John Wiley & Sons.

  • Chappell, K. J., Stoermer, M J, Fairlie, D and Young, P R (2006). Investigation of the West Nile virus NS3 protease by tandem use of site-directed mutagenesis and substrate modification. Australian Society for Microbiology Annual Scientific Meeting, Gold Coast, Qld, 2-6 July, 2006.

  • Young, P. R., Chappell, K. J., Stoermer, M. J., Fairlie, D., Kampmann, T. and Kobe, B. (2006). Multiple targets for antiviral inhibitors. 7th Asia Pacific Congress of Virology, New Delhi, 13-15 Nov, 2006.

  • Fairlie, D. (2006). New Treatment Strategies for Dengue and other Flaviviral Diseases. Norvatis foundations Symposium 277 on New Treatment Strategies for Dengue and other Flaviviral Diseases, Singapore, 26-27 September, 2005. Chichester, UK: John Wiley and Sons.

  • Fairlie, D., Singh, Y. and Sharpe, P. C. (2006). Peptide bundles: Loops, helices, strands and sheets. The American Chemical Society Meeting 2006, Atlanta, GA, USA, 26 -30 March, 2006. Washington: American Chemical Society.

  • Ma, M. T., Hoang, H. N., Beyer, R. L., Bryant, G. K., Appleton, T. G. and Fairlie, D. (2005). Alpha-helix induction in short peptides using metal clips. International Chemical Congress of Pacific Basin Societies (Pacifichem2005), Honolulu, Hawaii, 15 - 20 December 2005. WASHINGTON: AMER CHEMICAL SOC.

  • Chappell, K. J., Stoermer, M. J., Fairlie, D. and Young, P. R. (2005). Development of a catalytically active recombinant West Nile NS3 protease and the identification of key enzyme-substrate interactions by site-directed mutagenesis. 30th Lorne Conference on Protein Structure & Function, Lorne, 6-10 Feb, 2005.

  • Chappell, K. J., Stoermer, M. J., Fairlie, D. and Young, P. R. (2005). Development of a catalytically active recombinant West Nile NS3 protease and the identification of key enzyme-substrate interactions by site-directed mutagenesis. International Congress of Virology, San Francisco, 23-27 July, 2005.

  • Chappell, K. J., Stoermer, M. J., Fairlie, D. and Young, P. R. (2005). Development of a catalytically active recombinant West Nile virus NS3 protease and the identification of key enzyme-substrate and enzyme-cofactor interactions by site-directed mutagenesis. 3rd Australian Virology Group Meeting, Phillip Island, Vic., 9-12 Dec, 2005.

  • Shepherd, Nicholas E., Hoang, Huy N., Abbenante, Giovanni and Fairlie, David P. (2005). Modular alpha-helices: conformationally stable cyclic pentapeptides as alpha-turn mimetics. 3rd International Peptide Symposium/28th European Peptide Symposium, Prague, Czech Republic, 5-10 September 2004. Geneva, Switzerland: Kenes INT.

  • Levick, S., Taylor, S. M., Fairlie, D. and Brown, L. C. (2004). Cardiovascular structural and functional adaptations to group IIAsPLA2 inhibition. 2004 ISHR World Congress, Brisbane, Australia, 7-11/8/04. London: Academic Press.

  • Fairlie, DP (2004). Small molecules that mimic components of bioactive protein surfaces. Australia: CSIRO Publishing. doi: 10.1071/CH04074

  • Shepherd, N. E., Hoang, H., Abbenante, G. and Fairlie, D. P. (2004). Towards Modular Alpha-Helices: Comformationally Stable Cyclic Pentapeptides as Alpha-Turn Mimetics. 3rd International Peptide Symposium/28th European Peptide Symposium, Prague Czech Republic, Sep 05-10, 2004. GENEVA 1: JOHN WILEY & SONS LTD.

  • Fairlie, DP, Singh, Y, Sharpe, P and Stoermer, M (2003). Template-assembled peptide loops, helices, sheets and nanofibres. 225th National Meeting of the American-Chemical-Society, New Orleans Louisiana, Mar 23-27, 2003. WASHINGTON: AMER CHEMICAL SOC.

  • Beyer, R. L., Kelso, M. J., Hoang, H. N., Appleton, T. G. and Fairlie, D. (2003). Helix inducing metal clips in short peptides. Proceedings of the First International Symposium on Biomolecuy, Awaji, Japan, 2-5 December, 2003. Tokyo, Japan: Maruzen Co. Ltd..

  • Hoang, Huy N., Bryant, Gavin K., Kelso, Micheal J., Beyer, Renee L., Appleton, Trevor G. and Fairlie, David P. (2003). Short peptide alpha helices induced by multiple metal clips. 11th International Conference on Biological Inorganic Chemistry, Cairns, Australia, 19-23 July, 2003. New York, USA: Elsevier. doi: 10.1016/S0162-0134(03)80638-4

  • Hoang, Huy N., Bryant, Gavin K., Kelso, Micheal J., Beyer, Renee L., Appleton, Trevor G. and Fairlie, David P. (2003). Short peptide alpha helices induced by multiple metal clips. 11th International Conference on Biological Inorganic Chemistry, Cairns, Australia, 19-23 July 2003. New York, USA: Elsevier. doi: 10.1016/S0162-0134(03)80638-4

  • Gahan, Lawrence R., Cusack, Rodney M., Grondahl, Lisbeth H., Fairlie, David P. and Hanson, Graeme R. (2003). Studies of the interaction of potassium(I), calcium(II), magnesium(II) and copper(II) with cyclosporin A. 11th International Conference on Biological Inorganic Chemistry, New York, USA, 19-23July, 2003. New York, USA: Elseiver. doi: 10.1016/S0162-0134(03)80624-4

  • Fairlie, David P ., Singh, Yogendra, Sharpe, Philip and Stoermer, Martin (2003). Template-assembled peptide loops, helices, sheets, and nanofibers. 225th ACS National Meeting, New Orleans, LA, United States, 23-27 March 2003.

  • Kelso, MJ, Hoang, HN, Appleton, TG and Fairlie, DP (2002). Palladium induced alpha helicity in short peptides.. WASHINGTON: AMER CHEMICAL SOC.

  • Woodruff, T. M., Shiels, I. A., Fairlie, D. and Taylor, S. M. (2001). A new C5a receptor antagonist inhibits monoarticular arthritis in the rat. Complement Assoc. Diseases, Animal Models & Ther. Workshop, Santorini, Greece, 10-14 October, 2001. Aegean Conferences.

  • Fang, N., Arakaki, T., Fairlie, D., Martin, J. L. and Young, P. R. (2001). Construction and characterization of the dengue 2 virus NS3 protease and its mutants. 1st Australian Virology Group Meeting, Fraser Island, Qld, 5-9 December, 2001.

  • Appleton, T. G., Fairlie, D., Hoang, H. N., Kelso, M., March, D. R. and Oliver, W. (2001). Control of peptide conformation by Palladium(II) coordination. 10th International Conf on Bioinorganic Chemistry, Florence, Italy, 26-31 August, 2001. NEW YORK: ELSEVIER SCIENCE INC.

  • Young, P. R., Fang, N., Leung, D., Arakaki, T., Stoermer, M. J., Fairlie, D. and Martin, J. L. (2001). In vitro catalytic activity of recombinant forms of the dengue virus NS3 protease. 6th International Symposium on Positive Strand Viruses, Paris, France, 28 May - 2 June, 2001.

  • Appleton, T. G., Hoang, H. N., Fairlie, D., Kelso, M. and Bryant, G. K. (2001). Metal clips for folding peptides. World Chemistry Congress, Brisbane, 1-6 July, 2001.

  • Arumugum, T.V., Shiels, I. A., Fairlie, D. and Taylor, S. M. (2001). Prevention of ischemia/reperfusion injuries in rats by a new small molecule C5a receptor antagonist. Complement Associated Diseases, Animal Models and Ther. W/shop, Santorini, Greece, 10-14 October 2001. Aegean Conferences.

  • Fairlie, DP (2000). Complement and inflammation: New antagonists of C5a receptors.. WASHINGTON: AMER CHEMICAL SOC.

  • Appleton, T. G., Hoang, H. N. and Fairlie, D. (2000). Coordination with Pd(en)2+ imposes an a-helical structure on a pentapeptide. Pacifichem 2000, Honolulu, Hawaii, 14-19 December, 2000. American Chemical Society.

  • Young, P. R., Fang, N., Leung, D., Arakaki, T., Fairlie, D. and Martin, J. L. (2000). Expression and characterization of a catalytically active form of the Dengue virus NS3 protease. 1st Int Conf on Dengue and Dengue Haemorrhagic Fever, Chiang Mai, Thailand, 20-24 Nov, 2000.

  • Hanson, G. R., Bush, A. R. I., Fairlie, D. and Tyndall, J. (2000). Metallopeptides in Alzheimer's Disease. Brisbane Inorganic Chemistry Symposium, Dept of Chemistry, Uni of Queensland, 30 November 2000. Brisbane (UQ): Dept of Chemistry, UQ.

  • Hoang, H. N., Appleton, T. G. and Fairlie, D. (2000). The reaction between metal ions and short peptides. IC2000/11RACIC, Canberra, 6-11 Feb, 2000.

  • Stoermer, Martin and Fairlie, David (2000). Towards Arginine Mimetics. The First Brisbane Biological and Organic Chemistry Symposium, Griifith University, Brisbane, Queensland, Australia, 27th November 2000. doi: 10.6084/m9.figshare.7836131

  • Cusack, R., Grondahl, L., Abbenante, J., Fairlie, D., Gahan, L. R., Hambley, T. W. and Hanson, G. R. (1999). Cyclic peptides as metal ion receptors. IC'99, Wellington, NZ, 31 January - 4 February 1999. Wellington, NZ: NZ Institute of Chemistry.

  • White, H., Young, P. R., Brinkworth, R. I., Fairlie, D. and Leung, D. D. (1999). Homology model of the dengue 2 virus NS3 protease: Interactions with NS2B co-factor. XIth International Congress of Virology, Sydney, 9-13 August 1999. Sydney: International Union of Microbiological Societies.

  • Chalmers, David K., Stoermer, Martin J. and Fairlie, David P. (1998). Modelling Studies Of Molecular Receptors. Royal Australian Chemical Institute 16th National Organic Chemistry Conference, Leura, Blue Mountains, New South Wales, 12-17 July 1998.

  • Appleton, T. G., Prinsep, M. R., Fairlie, D. P., Lane, I. and Hanson, G. R. (1997). The selective binding of metal ions by tolyporphins. XXXI ICCC: International Conference on Coordination Chemistry, Vancouver, BC, Canada, 18–23 August 1996. Triangle Park, NC, U.S.A.: IUPAC Secretariat.

  • Cusack, R. M., Abernante, J., Gahan, L. R., Fairlie, D. P. and Hanson, G. R. (1996). Cyclic Peptides as Metal Ion Receptors. RACI Inorganic Division, IC '96, Townsville, Queensland, Australia, 30 June - 4 July, 1996.

  • Abbenante, G., Fairlie, D. P., Sokolenko, N., Gahan, L. R., Cusack, R., Hanson, G. R. and Pierens, G. K. (1996). Effects of conformational constraints in cyclic octapeptides of marine origin. 10th Brisbane Organic Chemistry Symposium, Brisbane, QLD, Australia, 29 November 1996.

  • Hanson, G. R., van den Brenk, A. L., Gahan, L. R., Fairlie, D. P. and Hawkins, C. J. (1996). Multifrequency EPR studies of the mono- and bi-nuclear copper(II) complexes formed with the marine cyclic octapeptides patellamide D and ascidiacyclamide. EPR-95: Electron Paramagnetic Resonance 1995 Satellite Workshop Meeting of the 12th International Society of Magnetic Resonance Conference (ISMAR'95), Sydney, NSW, Australia, 13-15 July 1995. Berlin, Germany: Springer Wien.

  • Lane, I., Prinsep, M., Hanson, G. R., Appleton, T. G. and Fairlie, D. (1995). Multifrequency EPR spectra of Cu(II) and Ag(II) tolyporphins. ISMAR 95: Twelfth Conference of the International Society of Magnetic Resonance, Sydney, NSW, Australia, 16-21 July 1995. Philadelphia, PA, U.S.A.: International Society of Magnetic Resonance (ISMAR).

  • Appleton, T. G., Prinsep, M. R., Fairlie, D. P., Lane, I., Hanson, G. R. and Moore, R. E. (1995). The selective binding of tolyporphins to metal ions. 10th National Convention RACI: The Royal Australian Chemical Institute's 10th National Convention: Chemistry Serving Society, Adelaide, SA, Australia, 27 September-2 October 1995. Adelaide, SA, Australia: ICI Australia.

  • ALEWOOD, PF, BAILEY, AJ, BRINKWORTH, RI, FAIRLIE, D and JONES, A (1993). CHARACTERIZATION OF TNF-ALPHA-RELATED PEPTIDES BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY MASS-SPECTROMETRY AND HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY TANDEM MASS-SPECTROMETRY. 12Th International Symp On High-Performance Liquid Chromatography of Proteins, Peptides and Polynucleotides, Sydney Australia, Nov 29-Dec 02, 1992. AMSTERDAM: ELSEVIER SCIENCE BV. doi: 10.1016/S0021-9673(99)87020-4

  • Mohan, P, Wong, MF, Verma, S, Huang, PP, Brinkworth, RI and Fairlie, DP (1993). Symmetrical and Nonsymmetrical Nonpeptide Inhibitors of Hiv-1 Protease - Naphthalenesulfonic Acid-Derivatives. WASHINGTON: AMER CHEMICAL SOC.

  • Fairlie, DP and Woon, TC (1992). Tautomerism in Amide Complexes. WASHINGTON: AMER CHEMICAL SOC.

  • Stoermer, M.J., Wickramasinghe, W., Weerasuria, K.D.V., Fairlie, D., Butler, D. and Warrener, R. (1992). Design and synthesis of new cavitands which are stereochemically rigid, hydrophobic and internally functionalised. Royal Australian Chemical Institute National Conference 1992, Monash University, Melbourne, Australia, 28 Sept - 2 October 1992.

  • Stoermer, Martin J. and Fairlie, David P. (1991). Synthesis of cavitands as catalytic environments. 12th National Conference of the Royal Australian Chemical Institute, Division of Organic Chemistry, University of Queensland, Australia, 1991.

Other Outputs

Grants (Administered at UQ)

PhD and MPhil Supervision

Current Supervision

  • Doctor Philosophy — Principal Advisor

    Other advisors:

  • Doctor Philosophy — Principal Advisor

    Other advisors:

  • Doctor Philosophy — Principal Advisor

    Other advisors:

  • Doctor Philosophy — Principal Advisor

  • Doctor Philosophy — Associate Advisor

    Other advisors:

Completed Supervision